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Abstract
Objective. Macrophage inflammatory protein 1-alpha (CCL3) is a chemokine that regulates macrophage trafficking to
the inflamed joint. The agonistic effect of CCL3 on osteolytic lesions in patients with multiple myeloma is recognized;
however, its role in skeletal damage during inflammatory arthritis has not been established. The aim of the study was to
explore the role of osteoclast-associated CCL3 upon bone resorption, and to test its pharmacological blockade for
protecting against bone pathology during inflammatory arthritis.
Methods. CCL3 production was studied during osteoclast differentiation from osteoclast precursor cells: human
CD14-positive mononuclear cells. Mice with CIA were treated with an anti-CCL3 antibody. The effect of CCL3 blockade
through mAb was studied through osteoclast number, cytokine production and bone resorption on ivory disks, and in vivo
through CIA progression (clinical score, paw diameter, synovial inflammation and bone damage).
Results. Over time, CCL3 increased in parallel with the number of osteoclasts in culture. Anti-CCL3 treatment achieved
a concentration-dependent inhibition of osteoclast fusion and reduced pit formation on ivory disks (P40.05). In CIA,
anti-CCL3 treatment reduced joint damage and significantly decreased multinucleated tartrate-resistant acid phosphat-
ase-positive osteoclasts and erosions in the wrists (P< 0.05) and elbows (P< 0.05), while also reducing joint erosions in
the hind (P< 0.01) and fore paws (P< 0.01) as confirmed by X-ray.
Conclusion. Inhibition of osteoclast-associated CCL3 reduced osteoclast formation and function whilst attenuating
arthritis-associated bone loss and controlling development of erosion in murine joints, thus uncoupling bone damage
from inflammation. Our findings may help future innovations for the diagnosis and treatment of inflammatory arthritis.
Key words: CCL3, macrophage inflammatory protein 1-alpha, osteoclast, collagen-induced arthritis, bone
erosion
Rheumatology key messages
. Inhibition of CCL3 produced by human cells attenuated osteoclast differentiation and osteoclast-associated
tissue resorption.
. The capacity of human osteoclasts to degrade bone tissue was unaffected by CCL3 antagonism.
. Pharmacological blockade of CCL3 during collagen-induced arthritis protected bones from erosion by reducing
joint-associated osteoclasts.
Introduction
A critical pathological feature of RA is the accumulation of
immune cells in joints. Macrophages are one of the first
cell types to infiltrate the inflamed synovia. They serve
multiple effector functions (e.g. cytokine and chemokine
production) and disrupt physiological bone remodelling
[1]. Enrichment in macrophage-derived products is a
characteristic feature of poor response to anti-rheumatic
treatment [2, 3] and higher numbers of circulating mono-
cytes predicted incomplete clinical response to MTX in
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untreated patients with RA [4]. Therefore, macrophages
are good targets for the treatment of RA and such bio-
markers can monitor clinical response.
Monocyte recruitment from the blood, their maturation
into macrophages and differentiation into osteoclasts are
vital in the advancement of RA [5]. These processes are
regulated by chemokines [e.g. monocyte chemo-
attractant protein 1 (CCL2), macrophage inflammatory
protein 1-alpha (CCL3) and regulated upon activation,
normal T cell expressed and secreted (CCL5)]. Such che-
mokines are induced during osseous inflammation [6!8]
and are readily detected in sera and SF of RA patients
with joint erosions [9, 10]. Collectively, these reports justify
the potential of CC chemokine blockade for the inhibition
of osseous inflammation and bone erosion during RA.
Surprisingly few clinical trials have tested chemokine
and chemokine receptor antagonism in treatment proto-
cols for RA [11!13].
Localized osteolysis of articular bone and more general-
ized bone loss (osteopenia and osteoporosis) in the axial
and appendicular skeleton are adverse characteristics of
a more severe RA that is associated with a higher degree
of functional disability and increased mortality [14, 15].
Bone resorption was thought to reflect the inflammatory
burden in rheumatoid joints but recent evidence suggests
the contrary. Biological anti-cytokine treatments (e.g.
infliximab, etanercept, adalimumab, tocilizumab) revealed
that inflammation could be uncoupled from progressive
skeletal damage in RA and that bone erosion was not
solely attributable to the action of TNF and IL-6 [16, 17].
Suppression of bone turnover through inhibition of RANK
ligand (RANKL) prevented increase of erosions and had
no evidence of an effect on activity measures of RA
[18, 19]. Additionally, subclinical inflammation in synovia
and tendons registered by MRI could cause erosion pro-
gress in absence of clinical signs of RA activity [19].
CCL2 [20], CCL3 [21] and CCL5 [22] are strongly linked
with osteoclast differentiation from CD14-positive precur-
sor cells arising from the monocyte!macrophage lineage.
In addition, administration of a neutralizing anti-CCL2 anti-
body reduced ankle swelling in the rat CIA model [23],
CCL3-deficient mice exhibited milder arthritis induced by
an anti-type II collagen mAb [24] and treatment with poly-
clonal anti-CCL5 antibody ameliorated adjuvant-induced
arthritis in rats [25]. Notably, the primary outcome for each
study was focused upon the assessment of inflammatory
indices. The impact of treatments on bone pathology was
not determined. The assessment of chemokine function in
these pre-clinical models of autoimmune arthritis supports
the potential of chemokine-targeting therapies to modify
disease progression and provided the rationale for this
study.
Here, we challenged the notion that CCL3 controlled
joint damage in arthritis solely by its pro-inflammatory
action and hypothesized osteoclast differentiation to be
the primary mode of action for CCL3. The aim of the
study was to explore the role of CCL3 during differenti-
ation of human osteoclasts upon resorption of ivory disks
and to test the efficacy of pharmacological blockade of
CCL3 on bone pathology in CIA. We identified CCL3 as a
chemokine produced in the course of osteoclast matur-
ation in direct proportion to bone erosion in vitro. An anti-
CCL3 antibody potently inhibited resorption of ivory disks
by osteoclasts without affecting CCL2, TNF or IL-6 levels
in culture, and uncoupled bone resorption from inflamma-
tion. During CIA, inhibition of CCL3 protected bones
against erosion by osteoclasts at a concentration that
had no substantial effect on joint inflammation.
Methods
Reagents
Flow cytometry antibodies (Anti-human CD14-FITC and
Isotype Control FITC) were purchased from
eBiosciences (Altrincham, UK). For human osteoclast dif-
ferentiation assays, M-CSF, RANKL, polyHistidine and
anti-CCL3 antibody (MAB270; murine raised IgG1 recon-
stituted with sterile PBS) were sourced from R&D
Systems, Abingdon, UK. Cell responses were compared
using media supplemented with mouse IgG1 isotype as a
control (MAB002, R&D Systems, Abingdon, UK).
Commercially available ELISA kits [CCL2, CCL3, CCL5,
IL-6, soluble IL-6 receptor (sIL-6R) and TNF-a] were run
in accordance with the manufacturer’s instructions (R&D
Systems, Abingdon, UK). Antibodies (R&D Systems,
Abingdon, UK) for CIA [anti-CCL3 (MAB450) and isotype
control (MAB006)] were reconstituted in sterile PBS.
Animals
Male DBA/1 (Charles River, Margate, UK) mice were used
for CIA assessments (ages 8!10weeks at initiation). All
procedures were approved by the Animal Welfare and
Ethical Review Body at Cardiff University, under the au-
thority of the Animal (Scientific Procedures) Act, 1986, and
were performed in accordance with Home Office-
approved license PPL 30/2928.
Osteoclast differentiation assay
Human samples were collected under ethical approval to
Cardiff Regional Experimental Arthritis Treatment and
Evaluation (CREATE) (Arthritis Research UK grant
Reference 20016 to A.S.W. and E.H.C.). Peripheral
blood mononuclear cells were isolated by Histopaque-
1077 (Sigma Chemicals, Poole, UK) density gradient cen-
trifugation from the venous blood of consenting healthy
human volunteers (Research Ethics Committee for Wales
Reference No. 12/WA/0045). Cells were washed three
times with sterile HBSS (Life Technologies, Grand
Island, NY, USA) and re-suspended in Roswell Park
Memorial Institute medium 1640 (Life Technologies,
Grand Island, NY, USA) supplemented with 10% heat-
inactivated FBS (Biosera, Labtech International, UK),
20mM L-glutamine, penicillin (50 U/ml) and streptomycin
(50 mg/ml), henceforth called complete medium. Human
monocytes and macrophages were positively selected
from peripheral blood mononuclear cells using CD14
MicroBeads (MACS, Miltenyi Biotech, Bisley, UK). Flow
cytometry confirmed 595% cells were CD14 positive.
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Purified CD14-positive cells were re-suspended in com-
plete medium (3.2 ! 106 cells/ml) and seeded onto ivory
disks to model cell/substrate interactions on bone matrix
[26]. CD14-positive cells were adhered to the ivory disks,
which were subsequently transferred into individual wells
containing 500ml of complete medium containing M-CSF
(10 ng/ml). After 7 days (day 0 of the osteoclast differenti-
ation assay) the expanded population of CD14-positive
osteoclast precursor cells (OCP) were cultured in
complete medium containing M-CSF (5 ng/ml), RANKL
(5 ng/ml) and polyHistidine (2.5 mg/ml). Antibodies (anti-
CCL3 and IgG1; both at a final concentration of 8 ng/ml)
were added on day 0 and replenished with each media
change (days 3, 7, 10 and 14) when supernatants were
collected. They were stored at "80#C until analysed by
ELISA. Disks were harvested at each media change for
time-course experiments or on day 14.
Tartrate-resistant acid phosphatase stain for OCP and
osteoclasts
Ivory disks were gently washed with PBS prior to cell fix-
ation by glutaraldehyde solution for 15min at 37#C.
Osteoclasts were detected by tartrate-resistant acid phos-
phatase (TRAP) stain and haematoxylin was used as a
counterstain to visualize nuclear material [27]. Cells were
counted manually (Corel Paintshop Pro software, Corel
Corporation, Ottawa, Canada) from images acquired by
light microscopy (total disk coverage 580%). Thirteen re-
gions of interest were photographed per disk (Olympus
Camedia C-3030 Digital Camera, Olympus UK & Ireland,
Southend-on-Sea, UK). Total cells, TRAP-positive OCP
and TRAP-positive osteoclasts [multinucleated cell (three
or more nuclei) of530mm diameter] were counted. A cali-
brated scale bar (ImageJ, National Institutes of Health,
Bethesda, MD, USA) measured cell dimensions.
Identification of resorption pits by toluidine blue
staining
Disks were rendered cell-free by scraping with 70% alco-
hol, bleached by H2O2 (1% v/v) overnight, washed in
water, stained with toluidine blue (0.5% w/v) for 60 s at
room temperature and rinsed until water ran stain free
[26, 28]. Pit borders were observed by light microscopy
and recorded (four low-power regions of interest per disk;
total coverage 580%). The area of disk resorbed by
osteoclasts was quantified using ImageJ software.
Quantification of resorption pit parameters by confo-
cal microscopy
Bleached disks were stained overnight with calcein
(0.025% w/v) at room temperature, individually mounted
(CyGel, Abcam, Cambridge, UK) and imaged by laser
scanning confocal microscopy (Nikon Eclipse TE300,
Nikon Instruments Europe BV, Amsterdam) linked to
LaserSharp 2000 software. Optimized data collection par-
ameters were kept constant for each disk (zoom: 1.5,
pixels-by-lines: 512 ! 512, step: 0.2 mm, xy pixel:
0.27mm, objective: !60 oil immersion 1.4NA). 3D data
(Z-stacks) were analysed by Metamorph (Molecular
Devices, CA, USA) to quantify individual pit characteristics
(lacuna area, perimeter, depth and volume). Pit parameters
were measured in at least n=2 disks per condition [volun-
teers (n=8) matched for each group (anti-CCL3 vs IgG1)].
Comparable regions of interest (n=10 per disk) were
acquired by steering the field of view East to West and
North to South via the centre point. Images were acquired
every 10th frame, approximately. 3D topography of the
disk surface was created with Fiji software (open source).
Anti-CCL3 therapy in CIA
CIA was induced as previously described [29]. In brief,
2mg/ml of chicken type II collagen (CII; Sigma-Aldrich,
Gillingham, UK) was emulsified with an equal volume of
complete Freund’s adjuvant. The emulsion (100 ml) was
injected near the base of the tail intra-dermally on days
0 and 21. Mice were randomly assigned two treatment
groups on day 21. Animals received five injections
(100 ml) containing 5.0mg/kg of either anti-CCL3 or iso-
type control administered intra-peritoneally on days 21,
23, 25, 27 and 28. Arthritis incidence and severity was
assessed daily; the maximum arthritis severity was
reached by one control mouse on day 29. Arthritis severity
in each paw (paw score) was assessed using an estab-
lished in-house scoring system: 0, normal; 1, mild but def-
inite swelling in the ankle or wrist joint or redness and
swelling limited to individual digits regardless of the
number of digits affected; 2, moderate swelling of ankle
or wrist; 3, severe redness and swelling of the ankle or
wrist and proximal phalangeal joints; 4, maximally
inflamed limb with involvement of multiple joints, no anky-
losis; and 5, maximally inflamed limb with involvement of
multiple joints, ankylosis present. The sum of scores for all
four paws provided the clinical score for each mouse.
Joint swelling was also measured by comparing calliper
measurements of the hind paws (paw diameter).
Histological assessment of CIA
Front limbs were fixed in formalin then decalcified in EDTA
[27, 28]. Histological sections (7mm) were cut from paraffin
wax blocks, stained with haematoxylin and TRAP and scored
using an established method. Synovial hyperplasia was
scored 0!3, inflammatory cells within the synovial tissue
were scored 0!5, inflammatory cells within the synovial
cavity were scored 0!3 and articular cartilage/subchondral
bone erosion was scored 0!3 [29, 30]. The composite score
gave an arthritis index for each section. TRAP-positive osteo-
clasts were counted manually in joints of the elbow and wrist.
X-ray for bone erosion quantification
Hind limbs were stripped of connective tissues and fixed
in ethanol (70% v/v) prior to radiological assessments.
Radiographs of the mouse paws were obtained using a
Kodak In vivo Imaging System FX, and images were as-
sessed using Kodak Molecular Imaging software (Kodak
Molecular Imaging Systems, Connecticut, USA) as
described previously [29]. A radiographic score was es-
tablished for each limb by counting the number of eroded
joints. The central/intermedium, fourth to fifth distal
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tarsals/fibulare, first to fifth metatarsal/tarsal and the first to
fifth phalangeal/metatarsal joints were counted (score= 1
for each eroded joint and maximum score=12 for each
limb). Two independent musculoskeletal clinicians who
were blinded to the CIA protocols scored the radiographs.
Statistics
Sample size estimation for quantifying the difference be-
tween two groups was calculated from absolute values
obtained from the first three osteoclast assays (G*Power
version 3.0.10, University of D €usseldorf, Germany). Eight
donors were required to achieve significance level of
P=0.05. Cells from each donor were tested in triplicate
for each condition (mean value reported graphically). The
total cell count for each disk in an individual well was used
to calculate cytokine and chemokine concentration
(picogram per millilitre) per well. Arthritis severity (by clin-
ical score) from historic data was used to calculate
sample size for CIA assessments; the minimum require-
ment to achieve significance level of P=0.05 was n=6 per
group. Collated data for all donors and for CIA experi-
ments are reported as mean (S.E.M.) unless stated other-
wise. Analysis of variance was used to determine
statistically significant differences between the means of
three or more independent groups. Where Student’s t-test
was used, the Bonferroni correction was applied to adjust
the P-values when several dependent or independent
statistical tests were performed simultaneously on a
single data set. Spearman’s rank correlation coefficient
was used to identify whether two variables were related
in a monotonic function. Two-way analysis of variance was
used to compare mean differences between groups by
two independent variables (time and concentration) and
by Chi-square, mid-P exact test. Analyses were performed
using GraphPad Prism v4 (GraphPad Software, San Diego
CA, USA), and the Open Source Epidemiologic Statistics
for Public Health version 3.0 (http://www.openepi.com).
P 40.05 were considered significant.
Results
Supplementation of human OCP by RANKL increased
CCL3 but not CCL2 or CCL5
CC chemokines (CCL2, CCL3 and CCL5) and pro-inflam-
matory cytokines (IL-6 and TNF-a) were prospectively mea-
sured in the culture media collected while CD14-positive
OCP differentiated into TRAP-positive OCP and multinuc-
lear osteoclasts. A significant time-dependent increase in
CCL3 levels was observed in cultures containing multinuc-
lear osteoclasts but not in undifferentiated macrophages
[Fig. 1A (i)]. There was a specific correlation between
CCL3 concentration and formation of TRAP-positive multi-
nucleated osteoclasts (P< 0.01). No such correlation was
observed with total cell counts [Fig. 1A (ii)] or TRAP-positive
FIG. 1 CCL3 was increased from OCP after RANKL supplementation
Human CD14-positive monocytes cultured on bone substrate (n = 8 donors) were maintained in M-CSF (closed circles) or
differentiated into osteoclasts (three or fewer nuclei) in M-CSF + RANKL medium (open circles). Media collected (days 0,
7, 10, 14) were analysed for CCL3 (A), IL-6 (B) and CCL2 (C) by ELISA. CCL3 increased significantly over the time-course
[A (i)] and correlated significantly with osteoclast count [A (ii)]. IL-6 (B) and CCL2 (C) in M-CSF, or M-CSF + RANKL
cultures, did not significantly change across the experimental time-course (one-way analysis of variance, post-
Bonferroni). Mean value for each donor plotted. *P < 0.05, **P < 0.01. OCP = osteoclast precursor cells.
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OCP (data not shown). IL-6 (Fig. 1B) and CCL2 (Fig. 1C)
were consistent across the time-course of the experiment
and showed no correlation to the numbers of differentiated
TRAP-positive OCPs. CCL5 and TNF-a levels were below
the detection limit of for the ELISAs (30 pg/ml for CCL5 and
15 pg/ml for TNF-a).
CCL3 correlates with bone resorption in vitro
In inflamed joints the autocrine effects of
osteoclast-associated CCL3 are difficult to distinguish
from the endocrine/exocrine effects of the chemokine.
Concentration-dependent inhibition of osteoclastogenesis
FIG. 2 CCL3 correlates with bone resorption in vitro
OCP (n = 8 donors, four replicates/condition) differentiated into osteoclasts in medium containing anti-CCL3 or IgG1
antibody. (A) Anti-CCL3 exerted a concentration-dependent inhibition on osteoclastogenesis (i), reducing total tartrate-
resistant acid phosphatase (TRAP)-positive cells (ii), multinucleated osteoclasts (iii) and resorption (iv). (B) Disks stained
with TRAP and haematoxylin (day 14). M-CSF cultures lacked osteoclasts (top), M-CSF + RANKL cultures showed strong
TRAP staining (bottom; scale bar = 50 mm). (C) Resorption pits visualized by toluidine blue (top, scale bar = 250 mm) or
calcein (bottom) reduced in anti-CCL3 (8 ng/ml) cultures vs IgG1 (yellow arrows). Mean value per donor plotted. *P 4
0.05, **P 4 0.01. OCP = osteoclast precursor cells.
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was observed using a CCL3 neutralizing antibody [Fig. 2A
(i)] without affecting the overall number of adherent cells
per disk. Formation of multinuclear TRAP-positive osteo-
clasts, but not TRAP-positive OCP, was inhibited by anti-
CCL3 [Fig. 2A (ii) and (iii), and Fig. 2B]. Supplementation of
M-CSF + RANKL cultures with IgG1 (8 ng/ml) had no sig-
nificant effect on TRAP-positive OCP or TRAP-positive
multinucleated osteoclast numbers. OCP cultured with
M-CSF and anti-CCL3 or control IgG1 did not differentiate
into TRAP-positive cells or multinucleated osteoclasts
(Fig. 2B). Resorption of bone substrate was significantly
reduced (P40.05) by anti-CCL3 [Fig. 2A (iv)]. Results
were consistent using two visualization methods namely,
light microscopy and confocal microscopy (Fig. 2C).
Resorption pit parameters were unaffected by CCL3
inhibition
The diversity of multinucleated TRAP-positive osteoclast
populations with respect to resorption and mobility is
defined by their ability to create pits and trenches on a
bone surface [31]. Topographical assessment of ivory
disks by confocal microscopy [Fig. 3A (i!iii)] revealed pit
characteristics indicative of stationary tissue resorption.
Osteoclast migration tracks were seldom observed in cul-
tures treated with anti-CCL3 or control antibodies. 3D
measurements of individual resorption pit parameters
demonstrated that anti-CCL3 treatment did not alter pit
surface area, perimeter, depth or volume [Fig. 3B (i)!(iv)].
Finally, we measured levels of cytokines and chemokines
with indirect effects on upon osteoclast-dependent disk
erosion. On day 14, the levels of pro-osteoclastogenic IL-
6, sIL-6R, CCL2 and CCL5 (only sIL-6R and CCL2 shown)
were not significantly different in the cell cultures treated
with anti-CCL3 compared with control cultures treated
with M-CSF + RANKL only (Fig. 3C).
Systemic inhibition of CCL3 reduced joint inflamma-
tion measured by histology
Diminutive, but not significant reductions in CIA-asso-
ciated clinical score and paw diameter inflammation
were observed in mice treated anti-CCL3 vs isotype con-
trol (Fig. 4A). Histological evaluation revealed a substantial
reduction of leucocyte infiltration into synovial tissues,
synovial hyperplasia and joint erosion by anti-CCL3 trea-
ted mice vs controls (Fig. 4B and C), resulting in a signifi-
cantly reduced arthritis index in the wrist (P< 0.01) and
elbow (P< 0.05) joint.
CCL3 antagonism substantially reduced bone
resorption in CIA
CCL3’s role in modulating experimental arthritis has
focused upon measuring synovitis and arthritis incidence
rather than bone pathology [24]. Here, we present experi-
mental evidence of the bone-protective effect of anti-
CCL3 treatment during CIA in mice using two independent
assessment methods. Firstly, histology showed that anti-
CCL3 treatment significantly reduced TRAP-positive OCP
in both the wrist (P< 0.05) and elbow (P< 0.05) joints
compared with the control mice treated with IgG1
(Fig. 5A).
Secondly, analysis of radiographs identified signifi-
cant differences in the extent of bone damage for both
hind paws (P< 0.05) and fore paws (P< 0.01) in anti-
CCL3-treated CIA mice vs controls (Fig. 5B and C).
Notably, radiographic bone erosions were detected in
the absence of visual signs of arthritis (arthritis score =
0), suggesting the uncoupling effects of anti-CCL3 treat-
ment on bone resorption from inflammation. Only 8% of
limbs from the control CIA mice were erosion free; the
remainder had erosions in three or more joints. Twenty-
one percent of limbs from anti-CCL3 treated mice were
erosion free, and an additional 17% had fewer than
three eroded joints. The number of erosion-free limbs
was significantly higher in anti-CCL3- vs IgG1-treated
mice (P= 0.02).
Discussion
CCL3 is a chemokine elevated in synovial fluid from pa-
tients with RA [32]. It is produced by several synovial cell-
types including fibroblasts, macrophages and neutrophils
[32!34]. Here, we emphasize a specific autocrine role of
CCL3 in regulating osteoclast function, which has not
been evaluated previously. We showed that inhibition of
CCL3 using monoclonal antibodies strongly attenuated
bone resorption by osteoclasts and arrested the develop-
ment of bone erosion in CIA. This supports the notion that
redressing the chemokine balance within the joint at an
early stage of arthritis is critical for preventing irreversible
bone damage and promoting a favourable outcome. In
previously reported pre-clinical and clinical assessments,
an inhibition of CCL3 binding to its receptor has been
utilized [35!37] rather than inhibiting the chemokine itself.
We studied biosynthetic aspects of osteoclastogenesis
and revealed CCL3 as the principle target for pharmaco-
logical intervention. CCL3 levels increased during osteo-
clast differentiation from human precursor cells and
correlated with the number of multinuclear TRAP-positive
osteoclasts but not with undifferentiated macrophages,
suggesting that CCL3 has a specific impact upon the mul-
tinucleation phase of osteoclast differentiation. Divergent
phase-specific effects for RANKL and M-CSF are also
described: increased DNA synthesis and proliferation in
the early stage and reduced proliferative activity in the
latter half of osteoclast differentiation [38]. Here we
show that pro-osteoclastogenic factors IL-6 and CCL2
were detectable in the culture media, but remain un-
affected by either RANKL supplementation or CCL3 neu-
tralization. In contrast to CCL3, their levels showed no
correlation with osteoclast number. These results identify
CCL3 as a priming agent for human osteoclast
maturation.
The presence of osteoclast-originated CCL3 increased
bone resorption whilst the inhibition of CCL3 prevented pit
formation in vitro. Irrespective of whether osteoclast dif-
ferentiation assays were conducted with or without anti-
CCL3, the pits were remarkably consistent in their dimen-
sions. This means that the resorptive function of the
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osteoclasts was unlikely to have been affected by CCL3
inhibition, showing opposing effects to TNF-a and RANKL
[39]. It has been proposed that CCL3 initiates pre-osteo-
clast differentiation indirectly by enhancing RANKL ex-
pression in mixed cell cultures derived from rat bone
marrow [40] and porcine marrow-derived cells [41]. Our
findings present important evidence for a direct ability of
osteoclast-produced CCL3 to coordinate and facilitate
differentiation of new osteoclasts contributing to the
bone microenvironment.
Cytokines like TNF-a and IL-6 are both pro-inflamma-
tory and osteolytic [42, 43]; neutralization of CCL3 did
change IL-6 production by human osteoclast in vitro
and may explain the modest effect of CCL3 neutraliza-
tion on signs of inflammation. Additionally, we were
unable to detect a change in CCL3 in the plasma of
CIA mice treated with anti-CCL3 antibodies (data not
shown), supporting the notion that anti-CCL3 was
working locally, and not systemically throughout the
murine system.
Histological evaluation of joints revealed a significant
reduction in erosive scores by the systemic administration
of anti-CCL3 antibody and protected CIA joints from skel-
etal damage. This was contrary to the clinical CIA data
where there was a small, but insignificant, reduction in
clinical score and paw diameter by CCL3 blockade.
Furthermore, X-ray analysis of joints revealed the pres-
ence of bone erosions in the absence of clinical signs of
arthritis. CCL3 inhibition was initiated at a very specific
time point when the formation of arthritogenic anti-colla-
gen antibodies was complete and while clinical signs of
arthritis were absent. To this end, the course of CIA
showed similarity with individuals at an early pre-clinical
phase of RA characterized by the production of antibodies
against citrullinated peptides, which utilize osteoclasts to
initiate a local influx of neutrophil to the joint via IL-8
[44, 45]. Our in vivo CIA data also support a role of
CCL3 in leucocyte infiltration within the diseased
joint, where leucocyte penetration into joint tissues
was substantially reduced in anti-CCL3-treated mice.
FIG. 3 CCL3 inhibition had no effect on resorption pit parameters
Calcein-stained ivory disks were imaged by fluorescence microscopy to quantify resorption pit parameters.
(A) Representative topographical maps of M-CSF (i), M-CSF + RANKL + IgG1 (ii), M-CSF + RANKL + anti-CCL3 (iii) disks
show their naturally undulating surface and resorption pits (spherical lacuna); scale bar = 40 mm. (B) Measured lacuna
area (i), perimeter (ii), depth (iii) and volume (iv) for anti-CCL3 vs IgG1 were unchanged (8 ng/ml). (C) Levels of CCL2 (i) and
sIL-6R (ii) were comparable in IgG1 and anti-CCL3 (8 ng/ml) cultures (day 14). Cells from healthy human volunteers (n = 6)
were cultured, n = 42 disks/condition, mean (S.E.M.) for each donor plotted.
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FIG. 4 Systemic inhibition of CCL3 reduced histological joint swelling
Mice with CIA received IgG1 or anti-CCL3 on days 21, 23, 25, 27 and 28 (5 mg/kg, n = 6/group). (A) Arthritis progression
monitored by clinical scores (i) and paw diameter (ii) saw no statistical differences (two-way analysis of variance).
(B) Representative tartrate-resistant acid phosphatase (TRAP) and haematoxylin-stained elbow joints from IgG1 (i) and
anti-CCL3 (ii). Assessment of inflammation (iii), erosion (iv) and arthritic index (v). (C) IgG1 wrist histology showed intense
TRAP-staining (i), which reduced in anti-CCL3 (ii), with significant reductions in inflammation (iii), erosion (iv) and arthritic
index (v). H = humerus, U = ulna, R = radius, C = carpal. *P 4 0.05, **P 4 0.01, scale = 1 mm.
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Hypothetically and in the correct environment, CCL3
could act in a similar way because it transforms into a
neutrophil-attracting chemokine after cytokine or hor-
mone priming [46!48].
Conclusion
This study shows that CCL3 produced by osteoclasts is a
potent regulator of bone resorption acting in the phase of
osteoclast multi-nucleation. Targeted inhibition of CCL3
using monoclonal antibodies strongly suppressed bone
formation of TRAP-positive osteoclasts and limited joint
damage and bone erosions in the CIA model. Our
observations enable us to propose a novel, autocrine con-
trol of bone environment and osteoclast differentiation by
CCL3. An anti-CCL3 antibody has never been tested in a
human RA trial. We present a justifiable case for the de-
velopment of innovative pharmacological solutions to in-
hibit CCL3 for treating inflammatory arthritis.
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